© 2022 MJH Life Sciences and Ophthalmology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
June 10, 2015
In this article, Dr Tanna discusses treatment options for glaucoma patients who do not show satisfactory response to a PGA while taking into consideration the two key therapeutic choice factors: IOP-lowering efficacy and tolerability.
Visus Therapeutics expands ophthalmic drug development portfolio with acquisition of ViewPoint Therapeutics' assets
The survey, from The Larry A. Greene Center and the Primary Care Collaborative, found that the COVID-19 pandemic has had an adverse impact on the well-being of physicians.
Myze launches for platform to engage 1 million dry eye patients by 2025: How Do Your Eyes Feel?